• 1
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 3364.
  • 2
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 3
    Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002; 36: 150155.
  • 4
    Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005; 42: 513.
  • 5
    Hino O, Kajino K, Umeda T, Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol. 2002; 37: 883887.
  • 6
    Umeda T, Hino O. Molecular aspects of human hepatocarcinogenesis mediated by inflammation: from hypercarcinogenic state to normo- or hypocarcinogenic state. Oncology. 2002; 62( suppl 1): 3842.
  • 7
    Ichida T, Van Thiel DH, Hassanein T. The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west. Hepatogastroenterology. 1996; 43: 15751583.
  • 8
    Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995; 221: 291298.
  • 9
    Hebbar M, Ernst O, Cattan S, et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology. 2006; 70: 154158.
  • 10
    Kim JH, Choi MS, Lee H, et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006; 21: 588594.
  • 11
    Kim SJ, Seo HY, Choi JG, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2006; 57: 436442.
  • 12
    Boige V, Taieb J, Hebbar M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer. 2006; 42: 456459.
  • 13
    Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 1987; 47: 707712.
  • 14
    Fausto N. Protooncogenes and growth factors associated with normal and abnormal liver growth. Dig Dis Sci. 1991; 36: 653658.
  • 15
    Fausto N, Mead JE. Regulation of liver growth: protooncogenes and transforming growth factors. Lab Invest. 1989; 60: 413.
  • 16
    Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology. 1997; 26: 14581466.
  • 17
    Neaud V, Faouzi S, Guirouilh J, Monvoisin A, Rosenbaum J. Hepatocyte growth factor secreted by human liver myofibroblasts increases invasiveness of hepatocellular carcinoma cells. Curr Top Pathol. 1999; 93: 195203.
  • 18
    Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001; 84: 13771383.
  • 19
    Fausto N, Mead JE, Gruppuso PA, Castilla A, Jakowlew SB. Effects of TGF-beta s in the liver: cell proliferation and fibrogenesis. Ciba Found Symp 1991; 157: 165174; discussion: 174–177.
  • 20
    Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol. 1999; 14: 453460.
  • 21
    Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep. 2005; 7: 241247.
  • 22
    Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep. 2002; 4: 317324.
  • 23
    Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10: 461466.
  • 24
    Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003; 12: 13951401.
  • 25
    Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003; 41( suppl 1): S43S48.
  • 26
    Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004; 6: 154161.
  • 27
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5892589.
  • 28
    Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2004; 6( suppl 1): S7S19.
  • 29
    Eckel F, von Delius S, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology. 2005; 69: 363371.
  • 30
    Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006; 107: 676685.
  • 31
    Moore MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol. 2005; 32: 56.
  • 32
    Duffaud F, Therasse P. [New guidelines to evaluate the response to treatment in solid tumors]. Bull Cancer. 2000; 87: 881886.
  • 33
    Llovet JM, Ruff P, Tassopoulos N, et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer. 2001; 37: 1352138.
  • 34
    Ruff P, Moodley SD, Papoport BL, et al. Pegylated liposomal doxorubicin (caelyx) in advanced hepatocellular carcinoma (HCC) [abstract]. Proc Am Soc Clin Oncol. 2000; 19; Abstract 1044.
  • 35
    Ruff P, Moodley SD, Rappaport BL, Vorobiof DA, Maart K, Chasen MR. Long term follow-up of pegylated liposomal doxorubicin (caelyx): a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC). Presented at The 37th Annual Meeting of the American Society of Clinical Oncology, May 12–15, 2001, San Francisco, California.
  • 36
    Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 18981903.
  • 37
    Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer. 2005; 103: 756762.
  • 38
    Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol. 2002; 13: 17711778.
  • 39
    Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev. 1988; 15: 131.
  • 40
    Simon R. Designs for efficient clinical trials. Oncology (Williston Park). 3: 4349, 1989; discussion 51–53.
  • 41
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 42
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 43
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 44
    Venables WN, Ripley BD. Modern Applied Statistics. New York: Springer; 1999.
  • 45
    Barbat V, Morin Y, Metge F, Hamard H. Carcinome hepatocellulaire: un cas de metastase orbitaire revelatrice. Revue de Medecine Interne. 2000; 21: 8690.
  • 46
    Daniele B, De Sio I, Izzo F, et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol. 2003; 36: 6367.
  • 47
    Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol. 2002; 8: 237242.
  • 48
    Zhao W, Ma Z, Zhou X, Feng Y, Fang B. [Prognostic value of CLIP score system for patients with resection of hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi. 2002; 40: 321325.
  • 49
    Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005; 23: 66576663.
  • 50
    Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology. 2002; 123: 20172027.
  • 51
    Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int. 2002; 1: 3541.
  • 52
    Moon WS, Chang KJ, Majumdar AP, Tarnawski AS. Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth. Digestion. 2004; 69: 219224.
  • 53
    Neo SY, Leow CK, Vega VB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology. 2004; 39: 944953.
  • 54
    Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 42934300.
  • 55
    Porta C, Ruf P, Feld R, et al. Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX). Presented at the 2006 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers. January 26–28, 2006, San Francisco, California.
  • 56
    Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 15321558.
  • 57
    Posey J, Johnson P, Mok T, et al. Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naive, unresectable hepatocellular carcinoma (HC). Presented at The 2005 American Society of Clinical Oncology Annual Meeting: Advancing the Science of Clinical Oncology, May 13–17, 2005, Orlando, Florida.
  • 58
    Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005; 23: 43384346.
  • 59
    Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005; 103: 749755.
  • 60
    Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004; 54: 385390.
  • 61
    Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003; 89: 1865189.
  • 62
    Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002; 94: 31863191.
  • 63
    Mok TS, Leung TW, Lee SD, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999; 44: 307311.
  • 64
    Meyskens FLJr, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs. 1998; 16: 171173.